**Introduction**

In the kidney, prostaglandins play a role in regulating renal hemodynamics, renin release, and tubular sodium and water reabsorption\(^1\text{--}^3\). The main renal prostaglandin (PG) is prostaglandin \(E_2\) (PGE\(_2\)) which is synthesized from arachidonic acid in the presence of cyclooxygenase isoforms cyclooxygenase-1 (COX-1) or cyclooxygenase-2 (COX-2) with the prostaglandin \(E\) synthase (PGES)\(^4\). The effects of PGE\(_2\) on renal water handling have widely been investigated\(^5\). Previous studies revealed that PGE\(_2\) plays a role in modulating the effect of vasopressin on osmotic water permeability in the renal collecting duct where it attenuates the anti-diuretic action of vasopressin. For example, 1) PGES inhibits both cAMP synthesis and elevation of cytosolic \(Ca^{2+}\) in rabbit cortical collecting ducts\(^5\) and rat terminal inner medullary collecting ducts, causing decreased trafficking of aquaporin 2 (AQP\(_2\)) to the apical plasma membrane; 2) PGE\(_2\) stimulation induces endocytosis of AQP\(_2\) in forskolin-stimulated Madin–Darby canine kidney (MDCK) cells, suggesting that PGE\(_2\) induces internalization of AQP\(_2\) independently of AQP\(_2\) dephosphorylation\(^6\); and 3) the diuretic effect of PGE\(_2\) also includes the cAMP and \(Ca^{2+}\)-independent activation of the Rho-kinase and formation of F-actin\(^8\).

**Key Words**: Aquaporins, Cyclooxygenase-2, Lithium, Prostaglandins

---

**Dysregulation of Renal Cyclooxygenase-2 in Rats with Lithium-induced Nephrogenic Diabetes Insipidus**

Tae-Hwan Kwon, M.D.

Department of Biochemistry and Cell Biology, Kyungpook National University School of Medicine, Daegu, Korea

This study aimed to examine whether the expression of major prostaglandin \(E_2\) (PGE\(_2\)) synthesis enzyme, cyclooxygenase-2 (COX-2), is changed in the kidneys of the rats with lithium-induced nephrogenic diabetes insipidus (Li-NDI). Sprague–Dawley rats treated with lithium for 4 weeks were used as the NDI model and expression of renal COX-2 was determined by immunoblotting and immunohistochemistry. In Li-NDI where urine output was markedly increased and urine osmolality was significantly decreased, COX-2 expression in the inner medulla was decreased (28% of control), while it increased 18-fold in the cortex and outer medulla. Consistent with this, labeling intensity of COX-2 in macula densa region was increased, whereas it was decreased in the interstitial cells in the inner medulla, indicating a differential regulation of COX-2 between the cortex and inner medulla in Li-NDI. Accordingly, urinary PGE\(_2\) excretion was significantly increased in Li-NDI. In conclusion, there is a differential regulation of COX-2 between cortex and inner medulla in Li-NDI and urinary PGE\(_2\) excretion is increased in Li-NDI, possibly due to an increased renal production. This may suggest that increased renal production of PGE\(_2\) could play a role in modulating water reabsorption in the renal collecting duct in Li-NDI.
catalytic activity. However their amino acid sequence and localization in the kidney are different\textsuperscript{1, 4).} COX-1 is believed to be constitutively expressed, whereas COX-2 is considered only to be induced during physiological stress\textsuperscript{1, 9).} Consistent with this, COX-2 expression has been demonstrated to be regulated by the interstitial osmolality in the inner medulla both \textit{in vivo} and \textit{in vitro}\textsuperscript{9).} Moreover, COX-2 expression is upregulated by dehydration in both normal rats\textsuperscript{1).} However, renal localization and regulation of these enzymes in conditions with water and sodium balance disturbance (e.g., diabetes insipidus) are not clearly understood. Lithium is an important drug widely used in the management of bipolar affective disorders\textsuperscript{10).} Lithium treatment, however, is associated with polyuria and decreased urinary concentrating ability in patients\textsuperscript{10).} The impaired urinary concentration ability and polyuria have been associated with impaired V\textsubscript{2}–receptor–mediated vasopressin responsiveness\textsuperscript{11) and decreased protein abundances of AQP2 and aquaporin 3 in collecting duct principal cells\textsuperscript{12).} Moreover, LiCl administration in rats induced a significant excretion of urinary PGE\textsubscript{2} along with polyuria and nonselective cyclooxygenase inhibitor, indomethacin treatment to rats with lithium–induced nephrogenic diabetes insipidus (Li–NDI) diminished urine volume and urinary PGE\textsubscript{2} levels\textsuperscript{13),} suggesting that cyclooxygenase–induced PG could be, at least in part, involved in the pathogenesis of Li–NDI.

The purposes of the present study were therefore to examine 1) the changes of expression and cellular localization of COX-2, the major PGE\textsubscript{2} synthesis enzyme, in the kidney inner medulla and cortex + outer medulla in rats with Li–NDI (vs. control rats); and 2) the changes of urinary excretion of PGE\textsubscript{2} in rats with Li–NDI (vs. control rats).

1. **Materials and Methods**

1. **Experimental animals**

The studies were performed on adult male Sprague–Dawley rats initially weighing 180–200 g (Hyochang Science, Daegu, Korea). The rats were maintained on a standard rodent diet with free access to water before the experiments.

2. **Experimental protocols**

Lithium chloride was added to the chow to give a concentration of 40 or 60 mEq lithium/kg of dry food as previously described\textsuperscript{12, 14).} Rats received food containing 40 mEq lithium/kg of dry food for the first 7 days and thereafter, 60 mEq lithium/kg of dry food for the following 3 weeks. Previously, we demonstrated that this protocol resulted in plasma lithium levels at therapeutic levels (0.8–1.3 mM) and minimized the weight loss caused by lithium\textsuperscript{14, 15).} For the last 7 days, both lithium–treated rats (n=6) and control rats (n=6) were maintained in metabolic cages to allow daily measurement of urine output and sample collections. They were supplied with the same amount of food per day (lithium–treated rats: 7 g/100 g of body weight of food containing 60 mEq lithium/kg of dry food or control rats: 7 g/100 g of body weight of food without lithium) to give a constant daily sodium intake. The rats were fed once daily in the morning, and ate nearly all of the offered food during the course of the day. All rats had free access to water intake.

3. **Semiquantitative immunoblotting**

All rats were killed under light enflurane anesthesia and the right kidneys were rapidly removed, dissected into two parts (i.e., cortex + outer medulla combined and inner medulla) and homogenized in ice-cooled isolation solution (0.3 M sucrose, 25 mM imidazole, 1 mM EDTA, 8.5 mM leupeptin, 1 mM phenylmethylsulfonyl fluoride, pH 7.2) using an Ultra–Turrax T8 homogenizer (IKA Labortechnik, Staufen, Germany). To remove whole cells, nuclei and mitochondria, the
homogenates were centrifuged at 4,000 g for 15 minutes at 4°C and the supernatant was pipetted off and kept on ice for further processing. The total protein concentration was measured (Pierce BCA protein assay reagent kit, Pierce, Rockford, IL) and all samples were adjusted with isolation solution to reach identical final protein concentrations. They were solubilized at 65°C for 15 minutes in Laemmli sample buffer, and then stored at −20°C. To confirm equal loading of protein, an initial gel was stained with Coomassie Blue dye, as described previously. SDS-PAGE was performed on 12% polyacrylamide gels. The proteins were transferred, incubated with antibodies, and the sites of antibody-antigen reaction were visualized, as previously described.

4. Immunohistochemistry

Left kidneys were fixed by retrograde perfusion via the aorta with 3% paraformaldehyde, in 0.1 M cacodylate buffer, pH 7.4. Immunolabeling was performed on sections from paraffin-embedded preparation (2 μm thickness) using methods described previously in detail.

5. Primary antibodies

For both semiquantitative immunoblotting and immunohistochemistry, previously well characterized anti-COX-2 polyclonal antibody (Cayman Chemical, Ann Arbor, MI) was used. Anti-rat AQP2 antibody (7661AP) was kindly presented by Dr. S. Nielsen, University of Aarhus, Denmark.

6. Measurements of urinary PGE₂

An enzyme immunoassay kit (Amersham Pharmacia Biotech, Little Chalfont, UK) was used to determine PGE₂ in the urine of experimental animals. The assay was performed according to manufacturer’s instructions. Fifty μL of urine sample or standard solution was mixed with assay buffer (0.1 M phosphate buffer pH 7.5, 0.9% bovine serum, 0.5% Kathon), PGE₂ antiserum and PGE₂-horseradish conjugate in provided microplate. The mixture was incubated at room temperature for 1 h on microplate shaker. After washing the enzyme, substrate (3,3′,5,5′ tetramethylbenzine/hydrogen peroxide) was applied to the microplate for 30 minutes. After stopping the reaction with 1 M sulphuric acid, optical density was measured at 450 nm. A standard curve was obtained using optical densities of standard samples and was used to determine the PGE₂ concentrations in the urinary samples.

7. Statistical analysis

Values are presented as mean±SE. Statistical comparison between experimental groups was accomplished by a standard unpaired t-test. p values less than 0.05 were considered as statistically significant.

Results

1. Chronic lithium treatment in rats was associated with polyuria, significantly decreased urine concentration and increased urinary PGE₂ excretion

Chronic LiCl treatment of rats for 4 weeks was associated with markedly increased urine output, compared with controls (578±83 vs. 43±3 μL/min/kg, p<0.05, Fig. 1A). Consistent with this, urine osmolality was significantly decreased in rats with Li-NDI (190±30 vs. 1,239±70 mOsm/kg H₂O, p<0.05, Fig. 1B), indicating that chronic lithium treatment in rats resulted in an impaired urinary concentration, as previously demonstrated. The 24-hour urinary PGE₂ excretion was significantly increased in rats with Li-NDI compared with control rats (262±42 vs. 88±7 ng/day, p<0.05, Fig. 1C).
2. Chronic lithium treatment in rats was associated with increased COX-2 protein expression in the kidney cortex and decreased COX-2 expression in the inner medulla

Chronic LiCl treatment markedly increased the expression of COX-2 in the kidney cortex and outer medulla to 1,845±618% of the control levels (100±18%, p<0.05, Fig. 2A, B). In contrast, COX-2 expression was significantly decreased in the kidney inner medulla to 28±7% of the control levels (100±24%, p<0.05, Fig. 2C, D). Immunoperoxidase labeling of COX-2 demonstrated an increased COX-2 labeling in the macula densa region of the cortical thick ascending limb in lithium-treated rats (indicated as MD in Fig. 3A) compared with the controls (Fig. 3B). Moreover, the number of COX-2 positive tubular cells was increased in lithium-treated rats (not shown). In the outer medulla, COX-2 immunolabeling was not observed in both lithium-treated rats and control rats (not shown), consistent with previous studies\textsuperscript{17}. In the
TH Kwon: COX-2 Expression in Lithium-induced NDI

In the inner medulla, weak but distinct COX-2 labeling was observed in a characteristic perinuclear pattern in inner medullary interstitial cells of kidneys from control rats (arrows in Fig. 3D), whereas no or very weak labeling of COX-2 was seen in the inner medulla of kidneys from lithium-treated rats (arrows in Fig. 3C). In contrast, COX-2 labeling was not seen in the collecting duct cells in both lithium-treated rats and control rats (Fig. 3C, D).

**Discussion**

The present study demonstrated that 1) there was a differential regulation of COX-2 between cortex and inner medulla in Li-NDI, thus, Li-NDI was associated with significantly decreased expression of COX-2 in the inner medullary interstitial cells, whereas COX-2 expression at the macula densa in the cortical thick ascending limb was markedly increased; and 2) urinary PGE$_2$ excretion was significantly increased in Li-NDI, possibly due to an increased renal production of PGE$_2$.

We demonstrated altered expression of renal COX-2 in rats with Li-NDI where urine concentration was significantly decreased. Li-NDI could be associated with reduced interstitial osmolality, as previously evidenced by the decreased expression of urea transporters UT-A1 and UT-B, and vasopressin-stimulated phosphorylation of UT-A1$^{18}$. Decreased inner medullary COX-2 expression observed in the present study is consistent with previous studies raising the possibility that decreased interstitial osmolality in inner medulla may play a role in the downregulation of inner medullary COX-2 expression$^{9}$. Moreover, recent studies demonstrated that dehydration resulted in an increase of inner medullary COX-2 expression in

---

*Fig. 3.* Immunoperoxidase labeling of cyclooxygenase-2 (COX-2) demonstrated an increased COX-2 labeling in the macula densa of the cortical thick ascending limb in rats with lithium-induced nephrogenic diabetes insipidus (indicated as MD in A) compared with the controls (B). In the inner medulla, weak but distinct COX-2 labeling was observed in a characteristic perinuclear pattern in inner medullary interstitial cells of the kidneys from control rats (arrows in D), whereas no or very weak labeling of COX-2 was seen in the inner medulla of the kidneys from Li-treated rats (arrows in C). Glo, glomerulus; IMCD, inner medullary collecting duct; MD, macula densa.
both Sprague–Dawley rats\textsuperscript{9} and in rats with Li–NDI\textsuperscript{17}, paralleled by an increased urine concentration. Therefore, the findings of decreased expression of inner medullary COX–2 in polyuric Li–NDI (present study) and the increased expression of COX–2 in response to dehydration\textsuperscript{9,17} may suggest that COX–2–derived prostaglandins could, at least in part, participate in the regulation of urinary water excretion.

In contrast to the down-regulation of COX–2 in the inner medulla, COX–2 expression in the kidney cortex was markedly increased, and the number of COX–2–labeled cells in the macula densa region of the ascending thick ascending limbs was increased by lithium treatment. In the macula densa region, it has been demonstrated that an increased COX–2 expression is associated with conditions exhibiting high renin levels, e.g., sodium restriction, angiotensin converting enzyme inhibition, and renovascular hypertension\textsuperscript{11}. In contrast, selective COX–2 inhibitors significantly decrease plasma renin levels and renal renin activity\textsuperscript{11}. Thus, the regulation of renin secretion in the juxtaglomerular apparatus mediated by macula densa could be dependent on the COX–2–derived prostanoids. Previous studies demonstrated that rats with Li–NDI are associated with an increase in urinary sodium excretion mainly due to dysregulation of epithelial sodium channel ENaC subunits in addition to the polyuria and impaired urinary concentration\textsuperscript{11}, thereby they are prone to the development of extracellular fluid volume contraction and hence high renin secretion. The increased level of COX–2 expression and the increased number of COX–2–labeled cells in the macula densa region are therefore consistent with the state of potential extracellular fluid volume contraction in Li–NDI.

We demonstrated that 24–hour urinary excretion of PGE\textsubscript{2} was significantly increased in rats with Li–NDI when compared with control rats. This is consistent with previous findings showing an increased urinary PGE\textsubscript{2} excretion in Li–NDI in both experimental animals and human patients as well as in patients with congenital forms of NDI\textsuperscript{13,19}. Since COX–2 expression in the kidney cortex was increased while the expression was decreased in inner medulla, it could be possible that measurements of PGE\textsubscript{2} in the urine do not reflect the inner medullary renal PGE\textsubscript{2} synthesis accurately or cortical COX–2 expression and PGE\textsubscript{2} production may mainly affect the urinary PGE\textsubscript{2} excretion. Thus, further studies are needed to understand the discrepancy between the increased urinary PGE\textsubscript{2} excretion and decreased expression of inner medullary COX–2 in Li–NDI.

The mechanisms by which lithium induces diabetes insipidus are incompletely understood. This study demonstrated that urinary PGE\textsubscript{2} excretion is increased, suggesting that Li–NDI could be associated with an increased renal production of PGE\textsubscript{2}. There is a number of evidence that PGE\textsubscript{2} directly inhibits solute reabsorption in microperfused thick ascending limbs as well as water and solute reabsorption in the collecting ducts\textsuperscript{20–22}. Moreover, acute infusion of PGE\textsubscript{2} into the normal animals has been shown to cause water diuresis\textsuperscript{3} and to inhibit water absorption in collecting ducts\textsuperscript{5}. PGE\textsubscript{2} therefore appears to antagonize the hydrosomatic effect of vasopressin and thus PGE\textsubscript{2} may counteract vasopressin action in Li–NDI, serving as local feedback regulators of the antidiuretic action of vasopressin. Consistent with this, a recent study demonstrated that COX–2 inhibition completely prevented lithium–induced polyuria and an increased urinary PGE\textsubscript{2} excretion in COX–1 null mice (COX–1$^{-/-}$ mice), suggesting that COX–2 and/or COX–1–induced increase in the PGE\textsubscript{2} production could play a role in the lithium–induced polyuria\textsuperscript{23}.

In summary, 1) there is a differential regulation of COX–2 between cortex and IM in Li–NDI; and 2) urinary PGE\textsubscript{2} excretion is markedly increased in Li–NDI, possibly due to an increased renal production. PGE\textsubscript{2} is therefore likely to play a role in modulating the effect of vasopressin on the water reabsorption in the renal collecting duct where it attenuates the anti-diuretic action of vasopressin in Li–NDI.
Acknowledgements

This research was supported by the Korea Science and Engineering Foundation grant funded by the Korean Government (MOST, R01–2007–000–20441–0) and Brain Korea 21 projects in 2006.

References

1) Harris RC, Breyer MD: Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 281:F1–F11, 2001
2) Harris RC: Interactions between COX–2 and the renin-angiotensin system in the kidney. Acta Physiol Scand 177:423–427, 2003
3) Berl T, Schrier RW: Mechanism of effect of prostaglandin E1 on renal water excretion. J Clin Invest 52:163–471, 1973
4) Campean V, Theilig F, Paliege A, Breyer M, Bachmann S: Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). Am J Physiol Renal Physiol 285:F19–F32, 2003
5) Hebert RL, Jacobson HR, Breyer MD: PGE2 inhibits AVP–induced water flow in cortical collecting ducts by protein kinase C activation. Am J Physiol 259:F318–F325, 1990
6) Zelenina M, Christensen BM, Palmer J, Nairn AC, Nielsen S, Aperia A: Prostaglandin E(2) interaction with AVP: effects on AQP2 phosphorylation and distribution. Am J Physiol Renal Physiol 278:F388–F394, 2000
7) Nadler SP, Zimpelmann JA, Hebert RL: PGE2 inhibits water permeability at a post-cAMP site in rat terminal inner medullary collecting duct. Am J Physiol 262:F229–F235, 1992
8) Tamma G, Wiesner B, Furkert J, Hahm D, Oksche A, Schaefer M, Valenti G, Rosenthal W, Klussmann E: The prostaglandin E2 analogue sulphprostanate agonizes vasopressin–induced antidiuresis through activation of Rho. J Cell Sci 116:3285–3294, 2003
9) Yang T, Schnermann JB, Briggs JP: Regulation of cyclooxygenase–2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol 277:F1–F9, 1999
10) Timmer RT, Sands JM: Lithium intoxication. J Am Soc Nephrol 10:666–674, 1999
11) Christensen S, Kusano E, Yusuﬁ AN, Murayama N, Dousa TP: Pathogenesis of nephrogenic diabetes insipidus due to chronic administration of lithium in rats. J Clin Invest 75:1869–1879, 1985
12) Kwon TH, Laursen UH, Marples D, Maunsbach AB, Knepper MA, Frokiaer J, Nielsen S: Altered expression of renal AQPs and Na(+) transporters in rats with lithium–induced NDI. Am J Physiol Renal Physiol 279:F552–F564, 2000
13) Sugawara M, Hashimoto K, Ota Z: Involvement of prostaglandinE2, cAMP, and vasopressin in lithium–induced polyuria. Am J Physiol 254:F863–F869, 1988
14) Nielsen J, Kwon TH, Praetorius J, Kim YH, Frokiaer J, Knepper MA, Nielsen S: Segment–speciﬁc ENaC downregulation in kidneys of rats with lithium–induced NDI. Am J Physiol Renal Physiol 285:F1198–F1209, 2003
15) Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S: Lithium–induced downregulation of aquaporin–2 water channel expression in rat kidney medulla. J Clin Invest 95:1838–1845, 1995
16) Kwon TH, Nielsen J, Kim YH, Knepper MA, Frokiaer J, Nielsen S: Regulation of sodium transporters in the thick ascending limb of rat kidney: response to angiotensin II. Am J Physiol Renal Physiol 285:F152–F165, 2003
17) Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX–1, COX–2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 288:F1053–F1068, 2005
18) Klein JD, Gunn RB, Roberts BR, Sands JM: Down–regulation of urea transporters in the renal inner medulla of lithium–fed rats. Kidney Int 61:995–1002, 2002
19) Hofer C, Vantyghem MC, Racicot A, Cappoen JP, Lefebvre J: Normal hemodynamic and coagulation responses to 1-deamino–8–D–arginine vasopressin in a case of lithium–induced nephrogenic diabetes insipidus. Results of treatment by a prostaglandin synthesis inhibitor (indomethacin). Horm Res 37:190–195, 1992
20) Hebert RL, Jacobson HR, Breyer MD: Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium. J Clin Invest 87:1992–1998, 1991
21) Hebert RL, Jacobson HR, Fredin D, Breyer MD: Evidence that separate PGE2 receptors modulate water and sodium transport in rabbit cortical collecting duct. Am J Physiol 265:F643–F650, 1993
22) Sonnenburg WK, Smith WL: Regulation of cyclic AMP metabolism in rabbit cortical collecting tubule cells by prostaglandins. J Biol Chem 263:6155–6160, 1988
23) Rao R, Zhang MZ, Zhao M, Cai H, Harris RC, Breyer MD, Hao CM: Lithium treatment inhibits renal GSK–3 activity and promotes cyclooxygenase 2–dependent polyuria. Am J Physiol Renal Physiol 288:F642–F649, 2005